-
TRUSTED AU LABORATORY
-
26 Mark Rd. Elizabeth South, SA - 5112
-
Same day delivery
Pull the syringe to:
(0.100ml)
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
Tirzepatide 60mg is a synthetic research peptide studied in relation to incretin pathway research, GIP receptor signalling, GLP-1 receptor signalling, glucose regulation models, appetite pathway research and broader metabolic research contexts.
Tirzepatide is commonly described as a dual receptor agonist because it acts on both glucose-dependent insulinotropic polypeptide receptors, known as GIP receptors, and glucagon-like peptide-1 receptors, known as GLP-1 receptors. The FDA Mounjaro label describes tirzepatide as a GIP receptor and GLP-1 receptor agonist, while PubChem lists tirzepatide with the molecular formula C225H348N48O68.
This product is supplied for laboratory research use only. It is not a medicine, supplement, weight loss product, diabetes treatment, appetite product, body composition product, metabolic treatment or injectable product for human use.
| Product Detail | Information |
|---|---|
| Product name | Tirzepatide |
| Development code | LY3298176 |
| Size | 60mg |
| Product type | Research peptide |
| Research category | Metabolic Research / Incretin Research |
| Common research interest | GIP, GLP-1, incretin signalling and metabolic pathway research |
| Peptide type | Synthetic lipidated peptide |
| Main receptor interests | GIPR and GLP-1R |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration, weight loss, diabetes treatment or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
| Tirzepatide | Synthetic peptide | Studied as a dual GIP and GLP-1 receptor agonist in metabolic research |
| GIP receptor activity | Incretin receptor pathway | Studied in relation to insulinotropic and metabolic pathway research |
| GLP-1 receptor activity | Incretin receptor pathway | Studied in relation to glucose, satiety and gastric-emptying pathway models |
| Lipidated peptide design | Fatty-acid modified peptide format | Studied for extended activity and albumin-binding behaviour |
| Molecular formula | C225H348N48O68 | Listed in PubChem for Tirzepatide |
| CAS number | 2023788-19-2 | Common chemical registry identifier |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports stability before reconstitution when stored correctly |
PubChem lists Tirzepatide with the molecular formula C225H348N48O68. Product identity, salt form, purity and batch information should always be confirmed through supplier documentation and the Certificate of Analysis.
Tirzepatide is studied as a dual agonist of two incretin-related receptor pathways: GIPR and GLP-1R. These pathways are commonly examined in metabolic research involving glucose regulation, insulinotropic signalling, appetite pathway models, gastric-emptying research and body-weight regulation studies.
The GIP receptor pathway is studied in relation to insulinotropic signalling, nutrient response and broader metabolic pathway research.
The GLP-1 receptor pathway is studied in relation to incretin biology, glucose-dependent insulin secretion, gastric-emptying models and satiety pathway research.
This dual-pathway research profile is the main difference between Tirzepatide and single GLP-1 receptor agonist research compounds. It is also different from Retatrutide, which is commonly discussed as a triple agonist involving GIP, GLP-1 and glucagon receptor pathways.
| Research Area | Tirzepatide |
| Main research category | Metabolic peptide research |
| Development code | LY3298176 |
| Common receptor focus | GIPR and GLP-1R |
| Research pathway interest | Incretin signalling, glucose regulation and appetite pathway research |
| Common study context | Diabetes, obesity and metabolic disease research contexts |
| Structure interest | Synthetic lipidated peptide with extended activity profile |
| Evidence limitation | Clinical medicine context does not make research vials approved for human use |
| Product limitation | Research use only, not approved for human use |
| Feature | Tirzepatide | Retatrutide |
| Research class | Dual receptor agonist | Triple hormone receptor agonist |
| Main receptor pathways | GIP and GLP-1 receptors | GIP, GLP-1 and glucagon receptors |
| Glucagon receptor activity | Not the same triple agonist profile | Yes, part of the triple agonist research profile |
| Common research interest | Incretin, glucose and appetite pathway models | Incretin, glucagon and energy expenditure models |
| Approved medicine context | Approved tirzepatide medicines exist, but are not equivalent to research-use products | Investigational molecule context varies by jurisdiction |
| Human-use claim | Not appropriate for this research product | Not appropriate for research products |
| Feature | Tirzepatide | Semaglutide |
| Research class | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| Main receptor pathways | GIPR and GLP-1R | GLP-1R |
| Common research interest | Dual incretin pathway research | GLP-1 pathway research |
| Metabolic research focus | Glucose, appetite, body-weight and incretin signalling models | Glucose, appetite and GLP-1 signalling models |
| Product positioning | Research peptide only | Approved semaglutide medicines exist, but are not equivalent to research-use products |
| Human-use claim | Not appropriate for this product | Only relevant to approved, regulated medicines |
| Strength | Product Page Positioning |
| Tirzepatide 20mg | Standard-strength research vial for protocol-specific concentration planning |
| Tirzepatide 40mg | Higher-strength research vial for laboratory concentration planning |
| Tirzepatide 60mg | High-strength research vial for larger protocol-specific research supply |
Tirzepatide strengths should be treated as product variants, not duplicate product pages. If multiple strengths are listed separately, each page should have a strength-specific title, meta description, slug, concentration table and internal links to reduce SEO cannibalisation.
| Common Online Claim | Safer Research-Use Wording |
| Weight loss | Studied in obesity-related clinical and metabolic research contexts |
| Appetite suppression | Studied in relation to incretin and satiety pathway research models |
| Diabetes treatment | Not an approved claim for research-use material |
| Fat loss | Better framed as metabolic and body-weight regulation research |
| Ozempic alternative | Not accurate or compliant for a research-use product |
| Mounjaro alternative | Misleading because approved medicines are not equivalent to research vials |
| Body transformation | Not an approved or appropriate product claim |
| GLP-1 peptide | Better framed as dual GIP and GLP-1 receptor pathway research |
Tirzepatide 60mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for weight loss, appetite control, obesity treatment, diabetes management, fat loss, body transformation, bodybuilding, anti-ageing, metabolic health, performance enhancement or general wellness use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for Tirzepatide 60mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 60mg Vial | Final Concentration |
| 1mL | 60mg/mL |
| 2mL | 30mg/mL |
| 3mL | 20mg/mL |
| 6mL | 10mg/mL |
| 10mL | 6mg/mL |
| 12mL | 5mg/mL |
| 20mL | 3mg/mL |
| 30mL | 2mg/mL |
| 60mL | 1mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities.
Before handling Tirzepatide 60mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
| Product vial | Contains lyophilised Tirzepatide peptide |
| Certificate of Analysis | Confirms batch-level testing information |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Storage Factor | Guidance |
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Storage Factor | Guidance |
| Storage condition | Follow validated research protocol |
| Labelling | Record concentration, date, diluent and batch number |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Light exposure | Protect from unnecessary light exposure where required |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, injection schedules or administration guidance.
Tirzepatide 60mg is not supplied for human or animal administration. It is a laboratory research-use product only.
Regulated tirzepatide medicines have product-specific prescribing information, formulation-specific administration instructions, sponsor-controlled quality systems and approved indications. Those instructions are not transferable to research-use peptide vials, different strengths, different suppliers or non-approved products. The FDA label refers to Mounjaro as a specific tirzepatide injection product with regulated indication, formulation and prescribing information.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
| Strength check | Confirmation that the 60mg vial strength matches the approved research protocol |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded or storage conditions are not followed.
Because Tirzepatide is widely discussed online in relation to weight loss, diabetes and GLP-1-style products, product pages should avoid wording that could be interpreted as encouraging human weight loss, appetite suppression, self-injection or treatment use.
| Always | Why It Matters |
| Check the Certificate of Analysis | Confirms batch-level information |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Use research-use wording only | Reduces misleading human-use interpretation |
| Clearly separate research vials from regulated medicines | Avoids unsafe and misleading comparisons |
| Clearly separate each strength variant | Reduces product confusion and SEO cannibalisation |
| Never | Why It Is Risky |
| Never use for self-injection | Product is research use only |
| Never sell or promote as a weight loss product | Creates human-use and compliance risk |
| Never make appetite suppression claims | Not an approved or appropriate product claim |
| Never make diabetes treatment claims | Not an approved or appropriate product claim |
| Never describe it as Ozempic, Mounjaro or Zepbound | Misleading because research vials are not approved medicines |
| Never compare it directly to approved obesity medicines as if equivalent | Misleading and clinically inappropriate |
| Never copy dosing from approved medicine labels | Formulations, strengths and approved contexts differ |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
| Never rely on social media protocols | They may be inaccurate, unsafe or non-compliant |
| Never reuse generic content from another Tirzepatide strength without changing the strength-specific details | This can create duplicate content and poor SEO clarity |
The table below is for concentration planning only. It does not represent dosage, injection quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
| 60mg | 1mL | 60mg/mL |
| 60mg | 2mL | 30mg/mL |
| 60mg | 3mL | 20mg/mL |
| 60mg | 6mL | 10mg/mL |
| 60mg | 10mL | 6mg/mL |
| 60mg | 12mL | 5mg/mL |
| 60mg | 20mL | 3mg/mL |
| 60mg | 30mL | 2mg/mL |
| 60mg | 60mL | 1mg/mL |
If a researcher adds 12mL of suitable research-grade diluent to a 60mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example.
Tirzepatide is a synthetic research peptide also known as LY3298176. It is studied as a dual GIP and GLP-1 receptor agonist in metabolic and incretin pathway research.
Tirzepatide is not only a GLP-1 receptor agonist. It is commonly described as a dual agonist because it is studied in relation to both GIP and GLP-1 receptor pathways.
No. Tirzepatide is commonly described as a dual GIP and GLP-1 receptor agonist. Retatrutide is commonly discussed as a triple agonist involving GIP, GLP-1 and glucagon receptor pathways.
Approved tirzepatide medicines exist in Australia for specific registered indications, but this research-use Tirzepatide 60mg vial is not an approved medicine and should not be supplied or described for weight loss, diabetes treatment, appetite control or human use.
Tirzepatide is studied because GIP and GLP-1 pathways are connected to incretin biology, glucose regulation, gastric-emptying models, appetite signalling and body-weight regulation research.
The active research compound is the same product type, but the total vial content is different. The 60mg vial allows different concentration planning for qualified research settings. It should be treated as a strength variant, not a separate therapeutic claim.
They can be separate pages if each strength has a unique title, meta description, slug, concentration table and internal linking. If the content is mostly identical, a variable product structure may be better for SEO.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
| PubChem Tirzepatide compound profile | Useful background on Tirzepatide identity, molecular formula and receptor pathway description. |
| FDA Mounjaro label | Useful context showing regulated tirzepatide medicine information is formulation-specific and not transferable to research vials. |
| TGA Mounjaro decision summary | Useful Australian context on approved tirzepatide medicine status for specific registered indications. |
Tirzepatide 60mg for qualified laboratory research only. Not for human or veterinary use.
